Calithera Biosciences Inc (NASDAQ:CALA) has received an average rating of “Buy” from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $8.25.
Several brokerages have recently weighed in on CALA. HC Wainwright reiterated a “buy” rating and set a $9.50 price objective (up previously from $7.00) on shares of Calithera Biosciences in a report on Friday, May 8th. BidaskClub upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, April 9th. ValuEngine upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a report on Tuesday, March 17th. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Monday, May 11th. Finally, SVB Leerink reiterated an “outperform” rating on shares of Calithera Biosciences in a report on Wednesday, March 11th.
In related news, VP Stephanie Wong sold 5,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $8.00, for a total value of $40,000.00. Following the sale, the vice president now owns 30,082 shares in the company, valued at approximately $240,656. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 17.20% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC raised its holdings in shares of Calithera Biosciences by 230.7% in the 1st quarter. AQR Capital Management LLC now owns 112,296 shares of the biotechnology company’s stock worth $499,000 after acquiring an additional 78,335 shares during the last quarter. Engineers Gate Manager LP bought a new stake in Calithera Biosciences in the 1st quarter worth about $68,000. Two Sigma Advisers LP grew its position in Calithera Biosciences by 35.8% in the 1st quarter. Two Sigma Advisers LP now owns 289,700 shares of the biotechnology company’s stock worth $1,286,000 after purchasing an additional 76,300 shares in the last quarter. Geode Capital Management LLC grew its position in Calithera Biosciences by 21.0% in the 1st quarter. Geode Capital Management LLC now owns 807,690 shares of the biotechnology company’s stock worth $3,586,000 after purchasing an additional 140,332 shares in the last quarter. Finally, Deutsche Bank AG grew its position in Calithera Biosciences by 12.2% in the 1st quarter. Deutsche Bank AG now owns 17,651 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 1,919 shares in the last quarter. Institutional investors own 68.41% of the company’s stock.
CALA stock opened at $6.27 on Friday. The firm has a market cap of $431.80 million, a price-to-earnings ratio of -3.62 and a beta of 2.36. The company has a quick ratio of 8.75, a current ratio of 8.75 and a debt-to-equity ratio of 0.05. Calithera Biosciences has a 12-month low of $2.45 and a 12-month high of $8.18. The company’s fifty day simple moving average is $6.26 and its 200 day simple moving average is $5.59.
Calithera Biosciences (NASDAQ:CALA) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.02). Research analysts expect that Calithera Biosciences will post -1.36 earnings per share for the current year.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Read More: What is the operating income formula?
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.